Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Recardio, Inc.

Home Clinical Trial Sponsors and OrganizationsRecardio, Inc.

Recardio, Inc.

ACTIVE

加利福尼亚州旧金山县, California, United Stateswww.recardio.euPrivate11–50 employeesEstablished: 2011-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

9

7 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2011

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

6

66.7%

Phase 2

2

22.2%

Phase 3

1

11.1%

Trial Status Distribution

Active, not recruiting

6

66.7%

Completed

2

22.2%

Not yet recruiting

1

11.1%

Clinical Trials

Trials sponsored by this organization (9)

Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction

Not yet recruiting

Sep 20234,100 participants

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

Active, not recruiting

Feb 2019140 participants

Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction

Dec 201849 participants

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

Active, not recruiting

Jul 2018140 participants

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

Active, not recruiting

May 2018140 participants

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

Active, not recruiting

Apr 2018140 participants

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

Active, not recruiting

Apr 2018140 participants

A clinical study in humans of a new drug (dutogliptin) with an existing drug (filgrastim) for use after a heart attack.

Active, not recruiting

Mar 2018140 participants

Page 1 of 2

Approvals

No approval data available

News

Kancera Advances Cardiovascular Drug Pipeline with Recardio Partnership and FDA Engagement

- Kancera AB has partnered with US biotech Recardio Inc. to create a cardiovascular disease-focused specialty care company, with Recardio licensing candidate drugs KAND567 and KAND145. - The company expects FDA pre-IND feedback for its planned phase IIb FRACTIVE study of KAND567 in acute myocardial infarction by the end of Q2 2025. - Top-line results from the ongoing KANDOVA phase Ib/IIa study evaluating KAND567 plus carboplatin in ovarian cancer are expected in Q3 2025. - Kancera plans to rebrand as Novakand Pharma in September 2025, reflecting its strategic focus on cardiovascular therapeutics.

On this page

Overview
Clinical Trials9
Approvals
News1

Back to Organizations